Redeye comments on the positive interaction with the FDA about ongoing CMC work for the planned phase III study of mitazalimab in pancreatic cancer.

Vitrolife

Hansa Biopharma

Xvivo Perfusion

Moberg Pharma

Cantargia

CellaVision

Alligator Bioscience

* The company is dependent on capital markets and key individuals. 

* The programmes are high-risk due to binary outcomes of clinical trials.

* Having a patented product on a regulated market usually means stable incomes once approved and running.

* Possibility of receiving upfront, milestone payments and royalties without further investments on the part of the company.

* Patents provide a clear moat.

* Alligator Bioscience lacks profitability across all measured metrics, including gross profit margin, operating margin, ROE, and ROA.
* The company shows no consistent revenue or earnings growth over the past five years, indicating challenges in commercializing its products or services.
* Financial health appears weak, with insufficient current assets to cover liabilities and a likely need to raise capital within 12 months.
* There's no evidence of positive cash flow or near-term prospects for achieving sustainable cash flow positivity, raising concerns about long-term viability.
* The company's financial situation suggests high risk, with no clear path to profitability or financial stability in the immediate future.

* Alligator Bioscience is not burdened by dividend obligations, allowing it to reinvest all available capital into research and development.
* The company's lack of debt-related metrics indicates it may have a clean balance sheet, potentially providing financial flexibility.

* Limited management tenure: Only one person in the senior team has a tenure exceeding five years, potentially impacting institutional knowledge and continuity.
* Lack of revenue and returns: The company currently has no income, limiting its ability to generate returns on investments or pay dividends.
* CEO's limited company-specific experience: The CEO has worked at Alligator for less than five years, potentially impacting deep understanding of the business.
* Unsuccessful capital raising: The last rights issue was not fully subscribed, indicating potential investor skepticism or financial challenges.
* Absence of founder involvement: The original founder is no longer involved in the business, potentially impacting long-term vision and corporate culture.

* Strong industry expertise: The CEO brings over 20 years of international experience in pharma and biotech, enhancing the company's strategic positioning and operational capabilities.
* Lean, decentralized organization: Alligator promotes self-direction and accountability, fostering innovation and adaptability within the company.
* Consistent strategy execution: Management has demonstrated ability to deliver on promises, exemplified by the early completion of the mitazalimab clinical program.
* Transparent investor communication: The company provides timely, direct business updates and maintains consistent focus on long-term value creation.
* Significant insider ownership: With insiders holding over 30% of shares, there's strong alignment between management and shareholder interests.